Day One Reports First Quarter 2023 Financial Results and Corporate Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) have been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 7,410,000 shares, an increase of 11.3% from the March 15th total of 6,660,000 shares. Based on an average daily trading volume, of 692,900 shares, the days-to-cover […]
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) had its target price decreased by Needham & Company LLC from $48.00 to $44.00 in a research report report published on Wednesday morning, The Fly reports. Needham & Company LLC currently has a buy rating on the stock. Several other research firms also recently issued reports on DAWN. […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 6,660,000 shares, a growth of 12.1% from the February 28th total of 5,940,000 shares. Approximately 14.6% of the company’s shares are sold short. Based on an average daily volume […]